Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
Official title: Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe/Severe Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
65
Start Date
2025-02-01
Completion Date
2029-07-01
Last Updated
2025-06-08
Healthy Volunteers
No
Interventions
Dose-attenuated IST and Hetrombopag
Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily for 24weeks.
Locations (1)
Red Blood Cell Diseases Center
Tianjin, Tianjin Municipality, China